Duchenne News Tags: Sarepta Therapeutics

Sarepta shares enrollment updates for SRP-9001-303 study.

Sarepta shares an update on the regulatory review of SRP-9001, a treatment of ambulant individuals with Duchenne muscular dystrophy who have a confirmed mutation of the DMD gene.

Sarepta Therapeutics Announces May 12, 2023 as Date of Advisory Committee Meeting for SRP-9001

Sarepta announces advisory meeting for SRP-9001, an investigational gene therapy for the treatment of Duchenne muscular dystrophy.

Sarepta announces official release of 2023-2024 Route 79 Duchenne Scholarship Program

Sarepta announces FDA filing and priority review for biologics license application for SRP-9001

Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy.

On September 13, 2022, Sarepta Therapeutics shared an update announcing that their EMBARK (SRP-9001-301) study is fully enrolled.

On Sept. 7, 2022, Sarepta Therapeutics announced the recipients for its Route 79, Duchenne Scholarship Program for the 2022-2023 academic year.

On Sept. 6, 2022, Sarepta Therapeutics announced that the Food and Drug Administration lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy.

On July 6, 2022, Sarepta Therapeutics shared new functional data across multiple studies from the clinical development program for investigational gene therapy SRP-9001.

On June 23, 2022, Sarepta shared news regarding the MOMENTUM study.

On June 9, 2022, Sarepta provided a community update on their actively recruiting clinical trial programs for Duchenne muscular dystrophy.